NOV Inc. Stock
There is an upward development for NOV Inc. compared to yesterday, with an increase of €0.20 (1.400%).
Currently there is a rather positive sentiment for NOV Inc. with 15 Buy predictions and 6 Sell predictions.
With a target price of 15 € there is a slightly positive potential of 6.19% for NOV Inc. compared to the current price of 14.13 €.
Our community identified positive and negative aspects for NOV Inc. stock for the coming years. 1 users see the criterium "Balance Sheet Risk" as a plus for the NOV Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of NOV Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of NOV Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| NOV Inc. | 1.400% | 1.692% | 5.885% | -2.249% | 2.133% | -25.265% | 19.886% |
| Cimc Enric Holdings Inc. | -2.350% | -4.598% | 3.750% | 0.000% | -1.190% | -8.237% | 95.755% |
| John Wood Group | -0.400% | -5.407% | 3.500% | -68.636% | -67.316% | -83.765% | -92.870% |
| Core Laboratories Inc. | -0.690% | -0.694% | 8.333% | -24.339% | -10.625% | -17.816% | -40.417% |
Comments
NOV (NYSE:NOV) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Show more
Ratings data for NOV provided by MarketBeat
NOV (NYSE:NOV) was given a new $19.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.
Show more
Ratings data for NOV provided by MarketBeat
NOV (NYSE:NOV) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $19.00 price target on the stock.
Show more
Ratings data for NOV provided by MarketBeat